Trovagene (TROV +8%) gets a pop today after granting Novartis (NVS) subsidiary Genoptix...
Trovagene (TROV +8%) gets a pop today after granting Novartis (NVS) subsidiary Genoptix licensing rights to incorporate its nucleophosmin protein, NPM1, into research and clinical testing services for acute myelogenous leukemia. Trovagene holds an exclusive patent on the protein. Terms of the agreement include upfront fees and royalty payments. Additional financial terms were not disclosed. Additionally, Roth Capital initiates the shares with a Buy and a price target of $11 a share.
From other sites
at Zacks.com (Mar 18, 2015)
at Zacks.com (Mar 17, 2015)
at Zacks.com (Mar 13, 2015)
at Zacks.com (Mar 10, 2015)
at Benzinga.com (Feb 6, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs